To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout

Time to Maximum Serum Concentration (Tmax)

To evaluate the Tmax of oral XNW3009 tablets, febuxostat and colchicine in patients with gout

Time frame: 100 days

Mean Terminal Phase Half-life (t1/2)

To evaluate the t1/2 of XNW3009 tablets, febuxostat and colchicine in gout patients

Time frame: 100 days

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

Data for number of participants who presented one or more adverse events (serious or non serious) was reported. An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.